{
    "clinical_study": {
        "@rank": "156622", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Determine the pharmacokinetics of sodium dichloroacetate (DCA) in patients\n      with congenital lactic acidemia.\n\n      II. Determine the efficacy of DCA in decreasing the frequency and/or severity of acute\n      episodes of acidotic illness, improving linear growth, improving neurological or\n      developmental function, or slowing neurological or developmental deterioration in these\n      patients."
        }, 
        "brief_title": "Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia", 
        "condition": "Lactic Acidosis", 
        "condition_browse": {
            "mesh_term": [
                "Acidosis", 
                "Acidosis, Lactic"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, cross over study.  Patients are\n      randomized to start with one of two different doses of sodium dichloroacetate (DCA).\n\n      Patients receive one of two doses of oral DCA for 6 months, then switch to the alternate\n      dose for 6 months.  This course is repeated once.\n\n      Patients are followed for up to 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of stable, persistent lactic acidemia Venous lactate at least 3 mM under\n             basal conditions defined as: At least 4 hours postprandial No concurrent illness\n\n        OR\n\n          -  Diagnosis of cerebral lactic acidemia with elevated lactic acid in CSF but not in the\n             blood\n\n          -  No organic acidemias or defective gluconeogenesis\n\n        --Patient Characteristics--\n\n          -  Hematopoietic: Hemoglobin at least 7 mg/dL\n\n          -  Hepatic: Bilirubin no greater than 3 times upper limit of normal (ULN) AST, ALT, or\n             GGT no greater than 10 times ULN\n\n          -  Renal: Creatinine no greater than 2 mg/dL\n\n          -  Cardiovascular: Ejection fraction at least 25%\n\n          -  Other: No hypoglycemia (blood sugar less than 50 mg/dL at no greater than 12 hours\n             fasting) No severe peripheral neuropathy interfering with normal activities of living"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004493", 
            "org_study_id": "199/14274", 
            "secondary_id": "UCSD-FDR001481"
        }, 
        "intervention": {
            "intervention_name": "sodium dichloroacetate", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "inborn errors of metabolism", 
            "lactic acidosis", 
            "rare disease"
        ], 
        "lastchanged_date": "July 9, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093-0652"
                }, 
                "name": "University of California San Diego School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Diego", 
            "last_name": "Bruce Barshop", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004493"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "University of California, San Diego", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1998", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2000"
    }, 
    "geocoordinates": {
        "University of California San Diego School of Medicine": "32.839 -117.277"
    }
}